Pharmacological treatments for fatigue associated with palliative care (Q24236457)

1

0 references

Frank Elsner

2

0 references

Norbert Krumm

3

0 references

Peter Trottenberg

Cochrane Database of Systematic Reviews

4

0 references

publication date

10 November 2010

0 references

published in

0 references

cites work

A randomized, double-blind, placebo-controlled trial assessing the impact of dexamphetamine on fatigue in patients with advanced cancer.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Amantadine treatment of fatigue associated with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

L-carnitine supplementation in patients with advanced cancer and carnitine deficiency: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Modafinil effects in multiple sclerosis patients with fatigue

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

The effect of donepezil on sedation and other symptoms in patients receiving opioids for cancer pain: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Modafinil to treat fatigue in amyotrophic lateral sclerosis: an open label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Bupropion sustained release treatment reduces fatigue in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Effects of a supraphysiological dose of testosterone on physical function, muscle performance, mood, and fatigue in men with HIV-associated weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

The effect of immunomodulatory treatment on multiple sclerosis fatigue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Effects of treatment for depression on fatigue in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

DHEA treatment for HIV+ patients: effects on mood, androgenic and anabolic parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Modafinil treatment of fatigue in patients with ALS: a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Fatigue in multiple sclerosis: multidimensional assessment and response to symptomatic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Modafinil for the treatment of fatigue in lung cancer: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

A randomised placebo controlled exploratory study of vitamin B-12, lofepramine, and L-phenylalanine (the "Cari Loder regime") in the treatment of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Grading quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Fatigue associated with multiple sclerosis: diagnosis, impact and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Fatigue in ambulatory AIDS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Exercise for the management of cancer-related fatigue in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

The assessment of fatigue: a practical guide for clinicians and researchers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Epidemiology of chronic non-malignant pain in Denmark.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Physiological basis of fatigue

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Clinically important changes in acute pain outcome measures: a validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Review of exercise intervention studies in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Palliative care for end-stage heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Fatigue in multiple sclerosis: definition, pathophysiology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

A systematic review of the scales used for the measurement of cancer-related fatigue (CRF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Drug therapy for the management of cancer-related fatigue

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Evidence-based treatment for cancer-related fatigue

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Management of cancer-related fatigue

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Amantadine for fatigue in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Fatigue in palliative care patients -- an EAPC approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Symptom management in the elderly cancer patient: fatigue, pain, and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Fatigue in multiple sclerosis: a rational approach to evaluation and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Controlled physical activity trials in cancer survivors: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Use of methylphenidate in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Management of fatigue in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

Amantadine, fatigue, and multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

7 January 2021

A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

7 January 2021

Self-care behaviours initiated by chemotherapy patients in response to fatigue

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

7 January 2021

Dextroamphetamine as a treatment for depression and low energy in AIDS patients: a pilot study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

7 January 2021

Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

7 January 2021

A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. The Canadian MS Research Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

7 January 2021

Amantadine therapy for fatigue in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

7 January 2021

Fatigue and cancer: causes, prevalence and treatment approaches

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

7 January 2021

Amantadine influences cognitive processing in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

7 January 2021

A double-blind, placebo-controlled trial of amantadine for the treatment of fatigue in patients with the post-polio syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

7 January 2021

The healthcare needs of chronic obstructive pulmonary disease patients in the last year of life

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

7 January 2021

Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

7 January 2021

Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

7 January 2021

Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

7 January 2021

Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006788.PUB2

7 January 2021

10.1002/14651858.CD006788.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1431553

1431553

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference